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a Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Klinik und Hochschulambulanz für Neurologie, 
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A B S T R A C T   
Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent, potentially irreversible adverse effect of 
cytotoxic chemotherapy often leading to a reduction or discontinuation of treatment which negatively impacts 
patients’ prognosis. To date, however, neither predictive biomarkers nor preventive treatments for CIPN are 
available, which is partially due to a lack of suitable experimental models. We therefore aimed to evaluate 
whether sensory neurons derived from induced pluripotent stem cells (iPSC-DSN) can serve as human disease 
model system for CIPN. Treatment of iPSC-DSN for 24 h with the neurotoxic drugs paclitaxel, bortezomib, 
vincristine and cisplatin led to axonal blebbing and a dose dependent decline of cell viability in clinically 
relevant IC50 ranges, which was not observed for the non-neurotoxic compounds doxorubicin and 5-fluorouracil. 
Paclitaxel treatment effects were less pronounced after 24 h but prominent when treatment was applied for 72 h. 
Global transcriptome analyses performed at 24 h, i.e. before paclitaxel-induced cell death occurred, revealed the 
differential expression of genes of neuronal injury, cellular stress response, and sterol pathways. We further 
evaluated if known neuroprotective strategies can be reproduced in iPSC-DSN and observed protective effects of 
lithium replicating findings from rodent dorsal root ganglia cells. Comparing sensory neurons derived from two 
different healthy donors, we found preliminary evidence that these cell lines react differentially to neurotoxic 
drugs as expected from the variable presentation of CIPN in patients. In conclusion, iPSC-DSN are a promising 
platform to study the pathogenesis of CIPN and to evaluate neuroprotective treatment strategies. In the future, 
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E-mail address: wolfgang.boehmerle@charite.de (W. Boehmerle).   
1 Indicates equal contribution. 
Contents lists available at ScienceDirect 
Neurobiology of Disease 
journal homepage: www.elsevier.com/locate/ynbdi 
https://doi.org/10.1016/j.nbd.2021.105391 
Received 23 March 2021; Received in revised form 6 May 2021; Accepted 7 May 2021   
Neurobiology of Disease 155 (2021) 105391
2
the application of patient-specific iPSC-DSN could open new avenues for personalized medicine with individual 
risk prediction, choice of chemotherapeutic compounds and preventive treatments.   
1. Introduction 
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the 
most common side effects of cytotoxic chemotherapy and is clinically 
characterized by altered sensation, sensory loss and neuropathic pain. 
CIPN not only further increases the burden of disease but often neces-
sitates reduction or even discontinuation of chemotherapy and thereby 
limits the patients’ prognosis (Boehmerle et al., 2014; Knauss et al., 
2019). About two thirds of patients who undergo cytotoxic treatment 
develop CIPN (Boehmerle et al., 2014; Seretny et al., 2014), and ther-
apeutic options are currently limited to termination of treatment, dose 
reductions or often ineffective symptomatic treatment (Smith et al., 
2013). Despite some genome wide association studies which suggest 
candidate single nucleotide polymorphisms to be associated with CIPN 
(Mahmoudpour et al., 2018), it is not yet possible to predict which pa-
tient will develop adverse effects and to what extent. Likewise, bio-
markers as well as clinically tested preventive strategies in patients are 
presently not available. Even though targeted therapies with antibodies 
or genetic approaches continue to transform modern cancer treatment, 
‘classic’ cytotoxic treatments still remain a pivotal part of routine cancer 
therapy for the foreseeable future (reviewed by Boehmerle et al. (2014), 
Knauss et al. (2019)). With an increasing number of cancer survivors, 
irreversible neurologic sequelae of chemotherapy such as CIPN present a 
major unmet medical need. The incomplete understanding of the un-
derlying pathophysiology of CIPN is partly due to a lack of adequate 
human disease models. With the generation of induced pluripotent stem 
cells (iPSC) from adult human cells (Takahashi et al., 2007; Hennig 
et al., 2019) and their further differentiation into cell types such as iPSC- 
derived sensory neurons (Chambers et al., 2012; Schwartzentruber 
et al., 2018) or cardiomyocytes (Burridge et al., 2014), otherwise inac-
cessible human tissue has become available to model human diseases in 
vitro. Previous studies demonstrated neurotoxic effects of antineoplastic 
therapy on commercially available neurons of the peripheral (Wing 
et al., 2017) and central (Wheeler et al., 2015) human nervous system 
and in neurons converted from peripheral-blood-derived neural pro-
genitors (Vojnits et al., 2019). Previously, iPSC-derived cardiomyocytes 
were shown to reflect patients’ individual susceptibility to doxorubicin- 
induced cardiomyopathy, indicating iPSC-based models to be a prom-
ising platform to study the effects of chemotherapy-induced toxicity in a 
patient-specific human disease model (Burridge et al., 2016). 
In the present study, we tested the suitability of iPSC-derived sensory 
neurons (iPSC-DSN) as a human cellular disease model of 
chemotherapy-induced neurotoxicity. We were interested whether 
neurotoxic chemotherapy in clinically relevant steady state concentra-
tions affects cell viability and axonal integrity in iPSC-DSN, and if these 
effects are substance specific compared with cytotoxic drugs which 
typically do not cause neuropathy. Using paclitaxel as a prototype of a 
neurotoxic chemotherapy, we analyzed the global transcriptome of 
sensory neurons before apparent cell death occurs, and evaluated if the 
previously reported neuroprotectant lithium (Mo et al., 2012) can 
replicate neuroprotective effects in the human iPSC-DSN model. We 
further tested if iPSC-DSN derived from two distinct donors may react 
differentially upon neurotoxic chemotherapy as observed from differ-
ential CIPN susceptibilities known from humans (Mahmoudpour et al., 
2018). 
2. Material and methods 
A detailed description is found in the Supplemental Material. 
2.1. iPSC lines 
iPSC-derived sensory neurons were differentiated from two estab-
lished stem cell lines (s.c. BIHi005-A https://hpscreg.eu/cell-line/ 
BIHi005-A and BIHi004-B https://hpscreg.eu/cell-line/BIHi004-B, 
Berlin Institute of Health Stem Cell Core Facility). These lines were 
derived by reprogramming of human dermal fibroblasts using Sendai 
viral vectors as described previously (Hennig et al., 2019; Fusaki et al., 
2009). Cells were maintained on growth factor reduced Geltrex (Gibco) 
in E8 media, which was exchanged daily. Cells were enzymatically 
clump-passaged every 2–4 days when >70% confluency was reached 
using EDTA (UltraPure™ 0.5 M EDTA, Thermo Fisher). 
2.2. Sensory neuron differentiation and maintenance 
The s.c. P2 protocol by Schwartzentruber et al. (2018) was applied for 
hiPSC differentiation (Fig. 1 A). In brief, confluent clump-passaged iPS- 
cells were single cell seeded at a density between 200.000 and 400.000/ 
well into 6-well plates (Falcon) coated with growth factor reduced 
Geltrex (Gibco) and cultivated in E8 media until 70–80% confluency 
was achieved, which usually required 48 to 72 h. On day 0, neural in-
duction was commenced by replacing E8 media with Knockout Serum 
Replacement Media (500 ml DMEM-KO [Gibco] supplemented with 130 
ml CTS KnockOut SR XenoFree Medium (Gibco), 1× MEM-Non-essential 
Amino Acid Solution (Sigma), 1× Glutamax (Gibco) and 0.01 mM 
β-Mercapto-ethanol (Gibco) containing the two small molecule in-
hibitors ‘2i’: 100 nM LDN-193189 (Sigma) and 10 μM SB-431542 
(Peprotech) to drive neuroectoderm differentiation. On day 3, ‘3i’ con-
sisting of 3 μM CHIR99021 (Sigma), 10 μM DAPT (Sigma) and 10 μM 
SU5402 (Sigma) were added to promote neural crest specification. On 
day 4, N2B27 media (500 ml Neurobasal-Medium [Gibco], 5 ml of N-2 
(100×) supplement [Gibco], 10 ml of B27-supplement (50×) without 
Vitamin A [Gibco], 1× Glutamax and 0.01 mM β-Mercapto-ethanol 
[Sigma]) was progressively phased in. From day 7 onwards, ‘2i’ addition 
was ceased but ‘3i’ continued to be added until Day 11 (Fig. 1 A). On day 
11, iPSC-DSN were reseeded or cryopreserved according to the protocols 
of Schwartzentruber et al. (2018) and Stacey et al. (2018), respectively, 
and as described in detail in Suppl. methods. On day 14, cells were treated 
with 1 μg/ml Mitomycin C (Sigma) for 2 h to eliminate few dividing non- 
neuronal cells. iPSC-DSN were maturated for at least four more weeks, 
and half media change was performed every 3–4 days with N2B27 
supplemented with BDNF, GDNF, βNGF and NT3 (all at 25 ng/ml, 
Peprotech). For this study, 12 independent differentiations were per-
formed, carried out by the same experimenter. 
2.3. Whole cell patch-clamp 
Whole cell patch-clamp experiments were performed between 
maturation day 33 and 37 on a multi-neuron patch-clamp setup (Peng 
et al., 2019; Peng et al., 2017) with extra- and intracellular solutions 
according to Namer et al. (2019). Glass pipettes were pulled from bo-
rosilicate glass capillaries (2 mm outer/1 mm inner diameter; Hilgen-
berg) on a horizontal puller (P-97, Sutter Instrument Company) with a 
pipette resistance of 5–8 MΩ. Recordings were performed in a sub-
merged recording chamber containing a geltrex-coated coverslip and 
perfused with an extracellular solution at room temperature containing 
in mM: 140 NaCl, 3 KCl, 1 CaCl2,1 MgCl2, 10 HEPES and 20 D-Glucose 
(pH 7.4) (Namer et al., 2019). Glass pipettes were filled with intracel-
lular solution containing in mM: 4 NaCl, 135 K-gluconate, 3 MgCl2, 5 
EGTA, 5 HEPES, 2 Na2-ATP and 0.3 Na3-GTP (pH 7.25) (Namer et al., 
2019). Cells were visualized by an infrared differential interference 
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contrast microscopy (Olympus BX-51WI) equipped with a digital camera 
(Olympus XM10). Recordings were performed using 4 Multiclamp 700B 
amplifiers (Molecular Devices) in current-clamp mode. Low-pass 
filtering was applied at 6 kHz using the amplifiers built in Bessel filter 
and digitized with a Digidata 1550 (Molecular Devices) at a sampling 
rate of 20 kHz. The pClamp 10.4 software package (Molecular Devices) 
was applied for data acquisition and analysis (Peng et al., 2017). Intrinsic 
electrophysiological properties: Series resistance was between 22 MΩ and 
70 MΩ and measured in voltage-clamp mode using a 200 ms long 10 mV 
pulse. Resting state membrane potential (RMP) was determined as the 
mean of a 10 ms long baseline before the first step current injection after 
switching to current clamp mode. Action potentials (AP) were elicited 
by injecting a set of 1 s long current pulses starting at an amplitude of 
− 100 pA increasing to 800 pA in increments of 50–300 pA. The first 
action potential elicited at rheobase was analyzed. A total of 11 cells 
were recorded. Up to 5 cells were recorded simultaneously. 
2.4. Calcium live-cell imaging 
Calcium imaging was performed as described previously (Von Der 
Ahe et al., 2018). iPSC-DSN were loaded with Fura-2 AM 5 μM (Life 
Technologies GmbH, Darmstadt, Germany) and 0.02% pluronic F-127 
(Life Technologies GmbH, Darmstadt, Deutschland) for 30 min at 37 ◦C 
in a standard HEPES buffered solution prepared as 130 mM NaCl, 4.7 
mM KCl, 1 mM MgSO4, 1.2 mM KH2PO4, 1.3 mM CaCl2, 20 mM Hepes 
and 5 mM glucose, pH 7.4. After incubation, cell cultures were washed 
with standard HEPES buffered solution, and 8-Chamberslides or 24-well 
plates were placed in an Olympus IX 81 microscope equipped with a 
Uplan FLN objective 40×/1.13 (Olympus Corporation, Tokyo, Japan). 
Fluorescence signals were detected by a cooled CCD-camera at 1 Hz, 
and data processed using Xcellence imaging software (Olympus). Ex-
periments were performed at room temperature. F340/380 ratios were 
calculated for all regions of interest (ROI) after background subtraction. 
Stock solutions were diluted in HEPES buffered solution and manually 
added in a 1:10 ratio to the wells to reach a final concentration of 1 or 10 
μM capsaicin (HelloBio), 1 or 10 μM icilin (Tocris) and 10 or 100 μM 
ATP (Tocris). An F340/380 increase of >20% of baseline was considered 
as response. Calcium imaging was performed between maturation day 
43 and 77 for both cell lines (Detailed description in Suppl. Mat. 1, 
Table 2). 
2.5. Compound preparation 
Paclitaxel (Adipogen), bortezomib (Cayman Chemical) and 5-fluoro-
uracil (Sigma) were dissolved in DMSO, and cisplatin (Sigma) in sterile 
0.9% NaCl to reach 6 mM stock solutions. Vincristine (Cayman Chemi-
cal), doxorubicin hydrochloride (Tocris) and lithium chloride (Sigma) 
were prepared as aqueous solutions with sterile water to reach a 1 mM or 
600 mM (lithium chloride) stock solution. Final concentrations of 1 nM 
to 100 μM (cisplatin) or 100 pM to 10 μM (all other substances but 
lithium, which was used in 10 to 1000 μM concentrations) were applied 
for 24 h for cell viability and cytotoxicity experiments, unless otherwise 
stated. Concentrations of the vehicles were 1/600 DMSO (for experi-
ments with paclitaxel, bortezomib and 5-fluorouracil), 1/100 NaCl 0.9% 
or water (for experiments with vinristine, doxorubicin) and 1/60 (NaCl 
0.9%, experiments with cisplatin). 
2.6. Comparative bright field imaging and automated microscopic imaging 
before and after 24 h of exposure to cytotoxic drugs 
Comparative bright field images were taken with Cell3 iMager Duos 
(Screen Holdings Co., Ltd.), using automated image acquisition before 
and after 24 h of incubation with the cytostatic drugs (paclitaxel 10 μM, 
bortezomib 10 μM, vincristine 10 μM, cisplatin 100 μM, doxorubicin 10 
μM, 5-fluorouracil 10 μM), or after 72 h following a 24 h incubation with 
concentrations close to the calculated IC50 (paclitaxel 1 μM, bortezomib 
10 nM, vincristine 100 nM, cisplatin 10 μM). Opera Phenix High Content 
Screening System (Perkin Elmer, USA) was used for live cell imaging. 
Cells were incubated with fluoresceine diacetate (FDA, in DMSO, Invi-
trogen™, F1303) at 5 μg/ml for 5 min in N2B27. Media was completely 
removed after image acquisition, and cells were incubated with the 
cytostatic drugs for 24 h until cells were stained again with 5 μg/ml FDA. 
Images were taken automatically at pre-defined regions of interest and 
manually compared, and representative images selected. 
2.7. Cell viability and cytotoxicity assays 
Antineoplastic drugs were added to iPSC-DSN cultured in 96-well 
plates and incubated for 24 h if not otherwise stated. For cell viability 
and cytotoxicity, MTT and proteases assays (Promega CytoTox-Fluor 
Assay and CytoTox-Glo Assay) were applied according to the manufac-
turers’ instructions and live/dead ratios of MTT/proteases assays were 
calculated and normalized to vehicle, as described previously (Von Der 
Ahe et al., 2018). The z-factor was calculated applying digitonin (200 
μg/ml, sigma) for 24 h on iPSC-DSN d13, resulting in a mean value of 
0.76 ± 0.13, indicating a large separation band (Zhang et al., 1999) (5 
experiments pooled, see Suppl. Mat. 1, Table 3). Experiments to evaluate 
lithium chloride as potential neuroprotectant were performed with the 
same setup, but in a 72 h treatment challenge. 
2.8. Transcriptome sequencing analyses 
iPSC-DSN were maintained in geltrex coated 6-well plates at 106 
cells/well as described above. After maturation until d44 - d49, three 
wells were either treated with DMSO at 1/6000 or paclitaxel at 1 μM for 
24 h, and RNA was harvested with the Aurum™ Total RNA Mini Kit 
according to manufacturers’ instructions, with a total RNA amount be-
tween 1.49 and 2.97 μg. RNA sequencing was performed by Brooks Life 
Sciences Genewiz® with PolyA selection for RNA removal, 2 × 150 bp 
sequencing configuration and 20–30 million reads per sample. 5 samples 
were analyzed (n = 3 DMSO treated vs. 2 paclitaxel treated). 
Computational Methods. RNA Seq reads were mapped to human 
genome (GRCh38.p7) with STAR-version 2.7.3a (Dobin et al., 2013) 
using the default parameters. We obtained on average 80.2% uniquely 
mapped reads per sample. Reads were assigned to genes with featur-
eCounts (Liao et al., 2014) with the following parameters: -t exon -g 
gene_id, gene annotation - Gencode GRCh38/v25. The differential 
expression analysis was carried out with DESeq2-version 1.22.1 (Love 
et al., 2014) using the default parameters. We kept genes that have at 
least 5 reads in at least 2 samples. Gene set enrichment analysis was 
Fig. 1. Morphological and functional characterization of iPSC-DSN. 
(A) Cells were cultured in E8 media until differentiation was commenced with dual SMAD inhibition (LDN19318, SB431542), followed by WNT activation 
(CHIR99021), Notch inhibition (DAPT) and inhibition of VEGF/FGF/PDGF (SU5402) for 11 days. Cells were cultured for at least 30 more days (maturation phase). 
(B-E) show representative phase contrast images of the differentiation, from stem cell colonies (B) to sensory neuron ganglia like structures (E). (F-G) show early 
neurons (d14) expressing peripherin (F) and TRPM8 (G). Ganglia-like structures (H) and extensively arborized neurons (I) were seen after maturation using live cell 
imaging with FDA, and J-M expressed typical markers of the peripheral nervous system (J, Peripherin; K, TRPM8; L, TRPA1; M, Peripherin and CGRP). Physiological 
resting state and action potentials were revealed in patch clamp experiments (N). >d40 iPSC-DSN were responsive to inflammatory stimuli (ATP, open circles 10 μM, 
filled circles 100 μM) and the TRPV1 agonist capsaicin (open circles 1 μM, filled circles 10 μM) and the TRPM8 agonist icilin (open circles 1 μM, filled circles 10 μM) 
in Ca2+ imaging experiments (O), and responded with a Transient Increase (Profile 1), Increase with Plateau (Profile 2) or Plateau (Profile 3, (P)), as quantitively 
shown in pie charts for the respective stimuli (Q). 
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carried out with R/tmod package (Zyla et al., 2019). 
2.9. Statistical analyses 
Data were analyzed using Prism v8 (Graphpad Software, San Diego, 
CA). Data were checked for Gaussian distribution using Shapiro-Wilk 
normality test and histograms. Normally distributed data were 
analyzed with two-sided t-tests (2 groups). Data with low sample sizes or 
data not fulfilling the criterion of normal distribution were analyzed 
with Mann-Whitney-U test (2 groups). Cell viabilities were compared 
with one-way ANOVA and corrected for multiple comparison using 
Holm-Sidak’s multiple comparison test (normally distributed data) or 
the Kruskal-Wallis test and corrected using the Dunn’s multiple com-
parison test (data which were not normally distributed). Dose-response 
curves were calculated with non-linear regression models using 
GraphPad Prism (Log inhibitor vs. response, three parameters). All ex-
periments with >d40 iPSC-DSN were replicated at least 3 times from at 
least 2 independently differentiated iPSC-DSN cultures (biological rep-
licates) with 4 technical replicates for each condition (see detailed 
description in Suppl. Material 1, Table 1 and Suppl. Figs. 5–19). Data 
points with more than two standard deviations from the sample mean 
were treated as outliers and excluded from analysis, which was the case 
in 1.66% of the analyzed wells (See Suppl. Mat. 1, Table 1). Normally 
distributed data are presented as mean ± SD. Not normally distributed 
data are shown as median with interquartile ranges. Results for all 81 
analyzed assays are shown in Suppl. Mat. 1, Figs. 5–19. 
2.10. Data availability 
Open data publishing guidelines were followed. Data are available in 
the Data-in-Brief-Co-Submission. RNA sequencing data discussed in this 
publication have been deposited in NCBI’s Gene Expression Omnibus 




3.1. Morphological and functional properties of iPSC-DSN 
Sensory neurons were differentiated from iPSCs generated from two 
different, healthy donors according to the protocol published by 
Schwartzentruber et al. (2018). Briefly, iPSC-DSN underwent 11 days of 
differentiation to derive early neurons followed by a minimum of 30 days 
of maturation to derive iPSC-DSN with typical functional properties of 
sensory neurons (Fig. 1 A), as described below. Differentiation was star-
ted when 70–90% confluency was achieved (Fig. 1 B) and, soon after 
replating, we observed pseudounipolar neuronal cells (Fig. 1 C). After 
mitomycin c treatment, the few proliferating cells were eliminated and 
neurons formed ganglia-like structures (Fig. 1 D). After 40 days, 
morphologically pure neuronal cultures were observed (Fig. 1 E). 
Early iPSC-derived neurons could be identified on day 14 by staining 
for peripheral sensory nervous system markers such as peripherin (Fig. 1 
F). At that time some cells already expressed transient receptor potential 
cation channel subfamily M member 8 (TRPM8) which plays a role for 
temperature (cold) sensation (Fig. 1 G). By day 40, we observed large 
ganglia with extensive axons (Fig. 1 H + I). Subsets of neurons expressed 
peripherin, calcitonine gene related peptide (CGRP), transient receptor 
potential cation channel, subfamily A member 1 (TRPA1) and TRPM8 
(Fig. 1 J-M) as well as the transient receptor potential cation channel 
subfamily V member 4 (TRPV4) (Suppl. Fig. 1 F). The channels are 
separately shown in Suppl. Fig. 1 A-G. 
We examined electrophysiological properties of the neurons through 
whole cell patch-clamp recordings on day 33–37 (Fig. 1 N). We recorded 
11 neurons which exhibited physiological resting membrane potentials 
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Fig. 2. Morphological changes of iPSC-DSN upon 24 h-treatment with neurotoxic drugs. 
iPSC-DSN incubated for 24 h with a DMSO control did not show signs of neurodegeneration (A-D). Axonal blebbing as a sign of axonal damage was observed for all 
the 4 cytotoxic drugs after 24 h of incubation, modestly for paclitaxel (E-H), moderately for bortezomib (I-L) and most apparent for vincristine (M-P) and cisplatin (Q- 
T). At low concentrations of cytotoxic drugs near the calculated IC50, signs of axonal damage were more sensitively seen using fluoresceine diacetate (FDA) dyed 
neurons and live cell imaging (right panels) than bright field images (left panels). Vertical white arrows indicate axonal blebbing, horizontal arrows highlight lost 
cells after 24 h incubation with cytotoxic drugs. 
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able to elicit action potentials upon step current injection exhibiting 
kinetics within the range of previous studies (amplitude = 88 ± 14 mV, 
half-width = 2.1 ± 1.1 ms, maximum rise slope = 123 ± 55 mV/ms) 
(Meents et al., 2019) (Suppl. Fig. 2 A-E). 
Calcium imaging experiments showed that 43 ± 29% (SD) of >d40 
iPSC-DSN (d43-d77) responded to adenosine trisphosphate (ATP) 
stimulation, an agonist of P2X/P2Y purinoreceptors which plays an 
important role for inflammatory pain. 25 ± 17% of the cells responded 
to capsaicin, an agonist of the TRPV1 receptor which plays an important 
role in nociception. Furthermore, 44 ± 25% of the cells responded to 
stimulation with icilin, a TRPM8 receptor agonist which implies that the 
receptors detected by immunofluorescence are indeed functional (Fig. 1 
O). The number of responding cells was comparable between different 
doses of ATP/capsaicin/icilin which suggests that already the lower 
dose elicited a response saturation (Fig. 1 O). In general, we observed 
three different response patterns: a transient response (profile 1), a tran-
sient response with subsequent plateau (profile 2) and a slow increase 
(profile 3) (Fig. 1 P). When we analyzed the response profiles for each 
stimulus, we found that most iPSC-DSN responded to ATP with a tran-
sient Ca2+increase or an increase with plateau (profile 1: 56 ± 33%, 
profile 2: 44 ± 33%). For capsaicin and icilin, all three response profiles 
were observed (capsaicin: profile 1: 41 ± 44%, profile 2: 25 ± 31%, 
profile 3: 36 ± 40%; icilin: profile 1: 28 ± 24%, profile 2: 29 ± 8%, 
profile 3: 44 ± 29%, Fig. 1 Q). In contrast, early iPSC-DSN (d14) showed 
low responses to very high concentrations of ATP but not to the other 
stimuli (1 mM ATP, Suppl. Fig. 2 F). Sequential stimulation of iPSC-DSN 
revealed a functional heterogeneity of cells within the cultures, with 
some iPSC-DSN sensitive to low concentrations of capsaicin (1 μM) and 
others only to higher concentrations (10 μM). Some cells reacted to icilin 
only but not to capsaicin (Suppl. Fig. 2 G), or to capsaicin and pH 6 or to 
either of the both stimuli (Suppl. Fig. 2 H), indicating differential 
sensitivity and specificity of different cells upon stimuli within the cul-
tures as observed in dorsal root ganglia (DRGs) derived from humans 
(Schoepf et al., 2020; Li et al., 2015). Responsiveness in Ca2+ imaging 
experiments was shown for the cell lines BIHi005-A and BIHi004-B, and 
for directly differentiated neurons and neurons matured after thawing 
(detailed list of experiments in Suppl. Mat. 1, Table 2). In conclusion, 
>d40 iPSC-DSN show morphological features typical for primary dorsal 
root ganglia neurons, electrical activity of neurons and express func-
tional receptors for environmental stimuli as would be expected in 
sensory neurons. 
3.2. Sensitivity of iPSC-DSN to different clinically relevant cytotoxic 
drugs in a 24 h treatment regimen 
In a next step, we were interested in how >d40 and early (d13) iPSC- 
DSN react to four clinically relevant drugs used for chemotherapy with a 
known neurotoxic side effect profile in comparison to two compounds 
which do not usually cause CIPN in humans. Pharmacological and 
clinical characteristics of substances used in this study are summarized 
in Table 1. 24 h-incubation with 1:600 DMSO (vehicle) did not lead to 
morphological changes of iPSC-DSN cell bodies or axons (Fig. 2 A-D). 
After 24-h exposure with 10 μM paclitaxel, no morphological changes 
were detected in bright field imaging (Fig. 2 E + F). Using live cell 
imaging with FDA, we observed axonal blebbing in some areas of the 
culture but not all, while cell bodies were mostly unaffected (Fig. 2 G +
Fig. 3. Effect of cytotoxic drugs on cell viability (24 h treatment). 
Curves show the calculated live/dead ratio from MTT and protease assays as mean viability with 95% confidence interval. (A-D) show dose-response curves of the 
tested neurotoxic drugs, and (E-F) demonstrate results from the incubation with the non-neurotoxic drugs doxorubicin and 5-fluorouracil, revealing high substance 
specificity. <d40 iPSC-DSN (black line) show IC50 close to the steady concentrations used in patients (grey shading), with early neurons (grey line) being more 
sensitive. Number of pooled experiments (>d40 neurons/d13 neurons): paclitaxel 7/3, bortezomib 9/4, vincristine 11/6, cisplatin 9/5, doxorubicin 3/3, 5-fluoro-
uracil: 4/3. All assays with the respective cell lines that were used are shown separately in Suppl. Fig. 5–18. 
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H). 24-h exposure to bortezomib induced axonal blebbing and frag-
mentation of the plasma membranes (Fig. 2 I-L). The most obvious 
morphological changes were observed for vincristine and cisplatin, 
showing the disappearance of cells, axonal blebbing and membrane 
fragmentation for vincristine (Fig. 2 M-P) and cisplatin (Fig. 2 Q-T). 
These changes were not present after the treatment with the non- 
neurotoxic drugs doxorubicin (Suppl. Fig. 3 A + B) and 5-fluorouracil 
(Suppl. Fig. 3 C + D). Morphological indicators of cell body and 
axonal damage were also observed in bright field microscopy if low 
concentrations of chemotherapy near the calculated IC50 were applied 
for 24 h, then removed, and imaged 48 h after removal. In contrast, no 
substantial changes were observed for vehicle (Suppl. Fig. 4 A-J). Effects 
were again smaller for paclitaxel (Suppl. Fig. 4 C–D) and bortezomib 
(Suppl. Fig. 4 E-F) but remarkable for vincristine and cisplatin (Suppl. 
Fig. 4 G-J). 
We evaluated the dose-dependent effects of chemotherapy with 
paclitaxel (PTX), bortezomib (BTZ), vincristine (VIN) and cisplatin (CIS) 
in >d40 and early iPSC-DSN. 24 h exposure of iPSC-DSN with PTX, BTZ, 
VIN and CIS led to a dose-dependent decline in cell viability with 
calculated IC50 in or close to the steady state concentration applied in a 
clinical setting in patients. In >d40 iPSC-DSN, paclitaxel showed the 
smallest effect sizes with a correspondingly high variability of the IC50 as 
not in all experiments stable plateaus were reached for the lowest and 
highest PTX concentrations (IC50 290 nm [95% CI 12–5933]). Early 
iPSC-DSN were more sensitive to PTX with an IC50 of 6.9 nM [95% CI 
2.2–19.5] which is two orders of magnitude lower than the clinically 
applied steady state concentration of about 0.5 μM in humans (Table 1, 
Fig. 3 A). For bortezomib, >d40 iPSC-DSN and early neurons showed an 
equal IC50 of 3.8 nM [95% CI 2.2–6.8 and 2.9–4.8] which is close to the 
clinically applied steady state concentration of 3.5–5 nM in humans 
(Table 1). The viability in concentrations between 10 nM and 10 μM was 
much lower in early iPSC-DSN indicative for a higher vulnerability of 
early iPSC-DSN to bortezomib (Table 1, Fig. 3 B). For vincristine and 
cisplatin, IC50 were higher in >d40 iPSC-DSN (vincristine: IC50 66.3 nM 
[95% CI 39.4–111.4]; cisplatin: 11.7 μM [95% CI 6.4–22.0]) than in 
early iPSC-DSN (vincristine: IC50 1.7 nM [95% CI 1.2–2.4]; cisplatin: 4.5 
μM [95% CI 3.2–6.4]) and close to the clinically applied steady state 
concentrations in humans of about 5–10 nM for vincristine and 2–14 μM 
for cisplatin (Table 1, Fig. 3 C–D. All 81 assays are shown separately 
and pooled in Suppl. Figs. 5–19). 
Fig. 4. Effects of prolonged incubation with paclitaxel or 5-fluorouracil, evaluation of lithium as potential neuroprotectant and transcriptome analyses of iPSC-DSN. 
(A) Shows the calculated live/dead ratio as mean viability with 95% confidence interval from MTT and proteases assays of iPSC-DSN incubated with paclitaxel for 72 
h or (B) 5-fluorouracil for 72 h. A decline in cell viability in clinically relevant ranges (grey shading) was detected for paclitaxel, but not for 5-FU. (C) Shows moderate 
neuroprotective effects of iPSC-DSN treated with paclitaxel at 100 nM for 72 h when cells were co-incubated with lithium at 0.05–0.5 mM. Curves show dot plots 
calculated from live/dead ratio of MTT and proteases assays. (D) Shows the expression of typical markers of the sensory nervous system in our iPSC-DSN sample 
(>d40) as revealed by global transcriptome analyses, while typical markers of stem cells were not expressed. Number of pooled experiments (>d40 neurons): 
paclitaxel n = 5, 5-fluorouracil n = 3, paclitaxel 100 nM and lithium n = 5. All assays pooled in Fig. 4 (A-C) are shown separately in Suppl. Fig. 5–19. Transcriptome 
data with tpm are given in Suppl. Mat. 2. 
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3.3. Substance specificity of iPSC-DSN 
As opposed to PTX, BTZ, VIN and CIS, the exposure of >d40 iPSC- 
DSN with the clinically non-neurotoxic chemotherapy substances 
doxorubicin and 5-fluorouracil only led to a decrease in cell viability in 
much higher than clinically relevant dosages with an IC50 of 409 μM for 
doxorubicin which is ~5000-fold higher than the usually observed 
steady state concentrations in humans (Table 1, Fig. 3 E-F). Early iPSC- 
DSN showed a relevant decline in cell viability with an IC50 for 
doxorubicin of 466 nM. For 5-fluorouracil, no IC50 could be calculated 
for >d40 iPSC-DSN nor early iPSC-DSN as no plateau was reached for 
the highest concentrations applied (10 μM), a concentration which is 
more than 10-fold higher than the clinically relevant steady state con-
centration (Table 1, Fig. 3 E-F). In conclusion, the treatment of >d40 
iPSC-DSN with neurotoxic chemotherapy in clinically relevant dosages 
induced neurodegeneration with a dose-dependent decline in cell 
viability which was not the case for non-neurotoxic chemotherapy 
drugs. 
Fig. 5. Transcriptome sequencing analyses of iPSC-DSN treated with 1 μM paclitaxel for 24 h. 
(A) Differential gene expression upon paclitaxel treatment. X-axis shows gene log2 fold changes, Y-axis is -log10 (adj.P-value). (B) Evidence plots for significantly 
deregulated gene sets. X-axis is the list of genes sorted by the adjusted p-value, Y-axis is the fraction of genes in this particular gene set. Bright colors show genes with 
adj. P-value <0.05. Red are up- and blue are down-regulated genes (more differentially-regulated genes and gene sets are given in Suppl. Mat. 2 and 3). (C) Panel 
plots show the top deregulated pathways from MsigDB Reactome gene set collection. The effect size represents the area under the curve (from Fig. 5 B). The 
brightness of the boxes shows the significance. 
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3.4. 72 h treatment of >d40 iPSC-DSN with paclitaxel but not with 5- 
fluorouracil leads to a decreased cell viability 
As only small effects on cell viability were observed for paclitaxel 
upon 24 h treatment (100pM: 108.8 [95% CI 104.2–113.8]; 10 μM: 92.2 
[95% CI 79.4–99.6]), we were interested if prolongation of the incu-
bation time increases neurotoxic effects of paclitaxel on iPSC-DSN. A 
prolonged incubation period is justified from a clinical standpoint, as 
paclitaxel-induced neurotoxicity in the peripheral nervous system usu-
ally develops only after more than 50% of scheduled cycles. As a control 
for substance specificity we chose the non-neurotoxic drug 5-fluoro-
uracil. We observed a dose-dependent decline of cell viability of >d40 
iPSC-DSN following 72 h paclitaxel treatment but not for 5-fluorouracil 
treatment (PTX: IC50 99.1 [95% CI 26.7–479.1] nM, cell viability 
100pM: 98.4% [95% CI 89.6–107.4%], 10 μM: 40.6% [95% CI 
27.5–51.6%]; 5-FU: IC50 287.7 nM [95% CI n.a.], see Fig. 4 A-B). This 
Fig. 6. Findings in iPSC-DSN cell lines 
derived from two different healthy donors. 
Curves show mean viability with 95% con-
fidence interval. IC50 in the scatter plots 
were calculated for each experiment sepa-
rately and given as median with inter-
quartile range. The cell line BIHi004-B 
showed lower viabilities after 24 h incuba-
tion with bortezomib (A), correspondingly, 
with a significantly lower IC50 (B), which 
also held true for vincristine (C–D). Viabil-
ities for cisplatin were similar between the 
cell lines (E), but again with lower calcu-
lated IC50 for BIHi004-B. Number of pooled 
experiments (cell line BIHi005-A/BIHi004- 
B): bortezomib 6/3, vincristine 6/5, 
cisplatin 5/4. All assays are shown sepa-
rately in Suppl. Fig. 5–18.   
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indicates preserved substance specificity for neurotoxic effects in >d40 
iPSC-DSN after prolonged treatment for 72 h. 
3.5. Evaluation of lithium as potential neuroprotectant in the iPSC-DSN 
model 
We next investigated lithium which was established in animal 
models as a neuroprotective compound for paclitaxel-induced neuro-
toxicity (Mo et al., 2012; Sanchez et al., 2020). We found that cytotoxic 
effects of a 72 h exposure to 100 nM paclitaxel can be partly prevented 
by co-incubation with clinically relevant concentrations of lithium 
chloride (50, 100, 500 μM). 100 nM paclitaxel exposure lead to a decline 
in cell viability of iPSC-DSN to 56.7% after 72 h (95% CI 50.9–62.5%) 
whereas the administration of 1 mM lithium-chloride did not affect cell 
viability as compared to vehicle (Vehicle: 100%, 95% CI 93.0–107.0; 1 
mM lithium-chloride: 95.0%, 95% CI 87.9–102.0, ANOVA p = 0.37). Co- 
incubation with 50, 100 and 500 μM of lithium-chloride attenuated the 
cytotoxic effects of 100 nM PTX as compared to co-incubation with 
lithium-vehicle (50 μM: 69.8% [95% CI 64.1–75.6%, ANOVA, p =
0.0079], 100 μM: 68.0% [95% CI 63.5–72.6%, ANOVA, p = 0.029], 500 
μM: 67.2% [95% CI 61.1–73.2%, ANOVA, p = 0.031], see Fig. 4 C). This 
indicates moderate neuroprotective effects of lithium-chloride in con-
centrations between 50 μM and 500 μM. 
3.6. Transcriptome sequencing analyses of iPSC-DSN treated with 1 μM 
paclitaxel for 24 h 
As effects on cell viability and axonal morphology were small after 
24 h of treatment with paclitaxel but remarkable after 72 h of treatment, 
we were interested how paclitaxel in a dosage above the IC50 affects the 
transcriptome of iPSC-DSN before cell death occurs, and if the model is 
capable of replicating genes and gene subsets known from animal ex-
periments. All 5 analyzed samples of iPSC-DSN (DMSO treated n = 3, 
paclitaxel 1 μM n = 2) expressed typical markers of iPSC-DSN according 
to Schwartzentruber et al. (2018) such as dorsal root ganglia homeobox 
(DRGX), Nav 1.8 (SCN9a) or Piezo-type mechanosensitive ion channel 
component 2 (Piezo2), whereas, expectedly, typical pluripotency 
markers such as NANOG or Oct-4 (POU5F1) were not expressed (Fig. 4 
D; transcripts per kilobase million [TPM] for all analyzed genes are 
given in Suppl. Mat. 2). 
RNA-Sequencing analyses revealed 319 significantly differentially 
(padjusted < 0.01) expressed genes out of which 227 were upregulated 
and 92 downregulated (Suppl. Material 3). 84 of the upregulated and 33 
of the downregulated changed expression by at least 2 fold (see volcano 
plot, Fig. 5, A). 
Upregulated genes involve known neuronal injury markers such as 
the Activation Transcription Factor (ATF3), stress-inducible proteins such 
as Sestrin-2 (SESN2), apoptosis associated genes such as Caspase 3 
(CASP3), the JUN proto-oncogene (JUN) or BCL2-interacting proteins 
such as BBC3 or Harakiri (HRK). Also, vasoactive substances and pain 
inducing neuropeptides of the calcitonine gene related peptide family 
such as CALCB and adrenomedullin (ADM) were found amongst the top 
50 differentially regulated genes. Other upregulated pain associated 
genes involve the Phosphoinositide Interacting Regulator Of Transient 
Receptor Potential Channels (PIRT) (Kim et al., 2008), and inflamma-
tion associated genes such as tumor necrosis factor alpha receptors 
(TNFRSF9, TNFRSF10B) or the Matrix Metalloproteinase 10 (MMP10). 
Four out of the top 50 differentially-expressed genes encode either 
mitochondrial enzymes (Mitochondrial Phosphoenolpyruvate Carbox-
ykinase 2, PCK2; Acyl-CoA Synthetase Short Chain Family Member 2, 
ACSS2) or proteins that influence mitochondrial function (BCL2 Binding 
Component 3, BBC3; Eukaryotic Translation Initiation Factor 2 Alpha 
Kinase 3, EIF2AK3) (Suppl. Mat. 3). 
Downregulated genes involve pathways of sterol homeostasis, 
glucose homeostasis and lipogenesis, e.g., 3-Hydroxy-3-Methylglutaryl- 
CoA Synthase 1 (HMGCS1), Insulin Induced Gene 1 (INSIG1) or ELOVL 
Fatty Acid Elongase 6 (ELOVL6) (Fig. 5 A; Suppl. Fig. 20). Gene set 
enrichment analysis outlined significant deregulation of genes involved 
in cholesterol biosynthesis pathways, PERK regulated genes and genes 
involved in amino acid transport across the membrane (Fig. 5 B-C; 
Suppl. Mat. 3). In summary, there is a significant overlap of the above- 
mentioned genes and gene sets outlined by unbiased global differential 
transcriptome analyses with pathways known from the literature of 
neuropathy, pain and neurodegeneration (discussed in more detail 
below). 
3.7. Susceptibility of iPSC-DSN derived from two different healthy donors 
to neurotoxic chemotherapy 
In a next step, we assessed sensitivity to cytotoxic drugs in iPSC-DSN 
derived from genetically different donors (cell lines BIHi004-B and 
BIHi005-A). Interestingly, we observed preliminary evidence for a dif-
ferential susceptibility of >d40 iPSC-DSN derived from these cell lines to 
neurotoxic chemotherapy with bortezomib, vincristine and cisplatin as 
measured by different IC50 and partly different viabilities in concen-
trations close to the IC50. In the case of bortezomib, IC50 concentrations 
were significantly lower in iPSC-DSN derived from donor BIHi004-B 
compared to donor BIHi005-A (median IC50 = 1.62 nM [95% CI 
1.1–1.67] vs. 4.70 nM [95% CI 3.80–9.80], Mann-Whitney-U, p = 0.024; 
Fig. 6 A + B). Cell viabilities pointed into the same direction and were 
numerically, but not significantly, lower in cells derived from donor 
BIHi004-B than BIHi005-A when incubated with 1 nM (median viability 
= 101.2 nM [95% CI 89.2–127.7 vs. 137.0 nM [95% CI 123.0–151.7], 
Kruskal-Wallis test p = 0.22). There were no remarkable differences in 
very high or very low concentration ranges (Fig. 6 A + B). For vincris-
tine, we observed a lower IC50 in cells derived from donor cell line 
BIHi004-B compared to BIHi005-A (median IC50 = 31.9 nM [95% CI 
11.3–49.2] vs. 85.3 nM [95% CI 42.8–237.6], Mann-Whitney-U, p =
0.017, Fig. 6 C + D), and lower cell viabilities in cells from the donor 
BIHi004-B than BIHi005-A at 1 nM (median 85.0 nM [95% CI 
72.8–86.7] vs. 107.3 nM [95% CI 102.2–118.1], ANOVA, p < 0.0001) 
and 10 nM (median 75.8 nM [95% CI 69.6–91.6] vs. 112.3 nM [95% CI 
104.6–125.4], ANOVA, p < 0.0001). There were no differences in cell 
viabilities for very low (100pM) or high (100 nM – 10 μM) vincristine 
concentrations (Fig. 6 C + D). Exposure to cisplatin likewise affected 
iPSC-DSN derived from donor BIHi004-B more than iPSC-DSN from 
donor BIHi005-A, with an IC50 which was again lower in cell line 
BIHi004-B than in BIHi005-A (median IC50 = 5.1 μM [95% CI 1.7–8.8] 
vs. 11.9 μM [95% CI 9.0–32.4], p = 0.016, Fig. 6 E + F). Taken together, 
these results suggest a higher susceptibility to neurotoxic chemotherapy 
of iPSC-DSN derived from the donor BIHi004-B than BIHi005-A in 
dosage ranges which are in or close to the clinically applied concen-
trations. This, however, has to be interpreted cautiously as we do not 
have any clinical data of the donors, and as they differ in sex and 
ethnicity. 
4. Discussion 
In summary, this study models biological effects of chemotherapy 
induced neurotoxicity in human iPSC-derived sensory neurons: We 
observed a dose dependent decline in cell viability in or close to clinically 
measured steady state concentrations of the neurotoxic drugs paclitaxel, 
bortezomib, vincristine and cisplatin after 24 h of treatment. This effect 
is substance specific, as no relevant decline was observed for doxoru-
bicin and 5-fluorouracil, cytotoxic drugs which do not typically induce 
CIPN. Correspondingly, morphological signs of neurodegeneration were 
observed for the neurotoxic drugs but not for the non-neurotoxic drugs 
or vehicle. Effects on cell viability and axonal integrity were small for 
paclitaxel after 24 h, but prominent if treatment was prolonged to 72 h. 
Substance specificity was preserved in the 72 h treatment regimen as 5- 
fluororuacil did not affect iPSC-DSN cell viability. We further investi-
gated paclitaxel induced neurotoxicity with global transcriptome 
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analyses in the interval before apparent cell death occurs, which revealed 
the differential expression of genes involved in neuronal injury, cell 
death and metabolic pathways, replicating known genes and gene sets 
from animal based disease models. Co-administration of paclitaxel with 
lithium partly prevented neurotoxic effects, demonstrating the appli-
cability of the human iPSC-DSN model to evaluate neuroprotective 
strategies. Cells differentiated from the donor BIHi004-B were more 
susceptible to neurotoxic compounds than cultures from the cell line 
BIHi005-A, which could be due to a donor-specific susceptibility of 
neurotoxic side effects as known from patients. 
4.1. Morphological signs of axonal damage 
The iPSC-DSN model was able to mimic the axonal damage induced 
by neurotoxic drugs. Axonal blebs are known to appear in still-viable 
cells when apoptosis is commenced and precede Wallerian degenera-
tion (Sebbagh et al., 2001; Wang et al., 2012). Correspondingly, previ-
ous histological analyses of rodent sciatic and caudal nerves after 
cytotoxic treatment showed axonal loss for paclitaxel, bortezomib, 
vincristine and cisplatin and reduced sensory nerve action potentials, 
which correlates with the finding of sensory axonal neuropathy in 
humans (Boehmerle et al., 2015). A decreased neurite growth was 
shown in early iPSC-derived peripheral neurons and induced sensory 
neurons after administration of cytotoxic drugs (Wing et al., 2017; 
Vojnits et al., 2019). In our study, all four tested neurotoxic substances 
led to axonal blebbing after 24 h-incubation in iPSC-DSN. The effect was 
most pronounced for vincristine and cisplatin, moderate for bortezomib 
and small for paclitaxel. Detection of morphological changes was more 
sensitive when cells were live cell stained with FDA compared to bright 
field microscopy. Remarkably, these morphological signs were also 
observed in bright field imaging when concentrations of vincristine and 
cisplatin at low dosages were applied for 24 h and the and observation 
by microscopy done 48 h after removal of the treatment. This indicates 
that neurodegenerative pathways may already be activated within the 
first 24 h without being phenotypically apparent yet. 
4.2. Effect of cytotoxic drugs on iPSC-DSN cell viability 
We found iPSC-DSN to be sensitive to all four tested neurotoxic drugs 
in clinically relevant concentrations in a 24 h treatment regimen as 
measured by cell viability assays. For the two drugs that do not cause 
neuropathy in humans, doxorubicin and 5-fluorouracil, no decrease was 
observed in clinically relevant concentrations (5-fluorouracil) or noted 
only in concentrations higher than clinically relevant steady state con-
centrations or only in d13 iPSC-DSN (doxorubicin), indicating high 
substance specificity of >d40 iPSC-DSN. In the case of paclitaxel, we 
observed small effects on cell viability after 24 h similar to findings from 
another recent study (Xiong et al., 2021), which is why we tested a 
prolonged treatment of 72 h. From a clinical standpoint, this can be 
justified as paclitaxel-induced neurotoxicity in the peripheral nervous 
system usually develops only after more than 50% of scheduled cycles 
(Boehmerle et al., 2014). In the case of longer incubation with pacli-
taxel, we observed pronounced effects which allow comparative ana-
lyses or evaluation of neuroprotective strategies. Substance specificity 
was preserved even after 72 h treatment as no decrease of cell viability 
or neuronal morphology could be detected for the non-neurotoxic drug 
5-fluorouracil. These findings suggest a 24 h treatment regimen is suf-
ficient to study neurotoxic effects of bortezomib, vincristine and 
cisplatin while 72 h should be used for paclitaxel. 
4.3. Transcriptome analyses of iPSC-DSN exposed to paclitaxel in the 
time interval before morphologically apparent cell death 
Unbiased global transcriptome analyses of iPSC-DSN exposed to 
paclitaxel showed a remarkable overlap with previously reported 
candidate genes that are upregulated in animal-based peripheral nerve 
injury models, such as the activation transcription factor 3 (ATF3) 
(Omura et al., 2015; Seijffers et al., 2007; Pereira et al., 2019), Dual 
Specificity Phosphatase 4 (DUSP4) (Chandrasekhar et al., 2021), stress- 
inducible genes such as sestrin-2 (SESN2) or the DNA Damage Inducible 
Transcript 3 (DDIT3) (Kallenborn-Gerhardt et al., 2013; Syc-Mazurek 
et al., 2017). Interestingly, genes which belong to apoptotic pathways 
such as Casp3, HRK, JUN or BCL2 Binding Component 3 (BBC3) were 
already activated in this time window before cell death or severe axonal 
injury is completed, and were previously reported to be involved in the 
pathogenesis of peripheral neuropathies (Feinberg et al., 2017; Hantke 
et al., 2014). 
The top-50 differentially expressed genes also involved the pain 
inducing nociceptive peptides calcitonine gene related peptide (CALCB) 
or adrenomedullin (ADM) which co-mediate migraine or paclitaxel 
induced neuropathic pain (Pittman et al., 2014; Li et al., 2018). In this 
context, we also found an upregulation of the gene encoding PIRT 
[Phosphoinositide Interacting Regulator of TRP], a nociceptor membrane 
protein sensitizing TRPV1 channel activity (Kim et al., 2008) as well as 
inflammatory pathways, e.g., TNF alpha receptors and a matrix metal-
loproteinase which were reported to be involved in peripheral and 
central pain modulation (Spicarova et al., 2011) and CIPN (Gu et al., 
2020). Interestingly, four of the top 50-differentially expressed genes 
encoded either mitochondrial enzymes (PCK2, ACSS2) or proteins 
involved in mitochondrial function (BBC3; EIF2AK3) (Stelzer et al., 
2016). This is noteworthy as changes in mitochondrial bioenergetics 
were recently reported in paclitaxel-induced neuropathies (Xiong et al., 
2021; Duggett et al., 2017) and preclinical neuritis models (Muke et al., 
2020). It should be evaluated if these genes translate into protein and 
function, e.g., measuring pain associated-neuropeptides, changes of 
electrophysiological properties or sensory neuron bioenergetics in 
relation to the clinical phenotype once patient-specific iPSC-DSN are 
available. 
Significantly downregulated genes were found to be enriched in 
cholesterol biosynthesis and fatty acid metabolism pathways which are 
necessary for axon regeneration (Goodrum et al., 2000), and knockdown 
of these candidates has been shown to be involved in the pathogenesis of 
peripheral neuropathy (Cermenati et al., 2015). Recently, down-
regulation of the same gene cluster of cholesterol synthesis enzymes 
(DHCR24, MSMO1, IDI1 and HMGCS1) was reported in an animal model 
of central neurodegeneration (Canet-Pons et al., 2021), and the upre-
gulation pERK associated genes corroborates recent findings of 
paclitaxel-induced neuropathy in cultured rodent DRGs (Li et al., 2021). 
Albeit differential transcriptome analyses in iPSC-DSN remarkably 
parallel some previously described genes and gene sets from animal 
experiments or chronic pain conditions (Li et al., 2021; Wangzhou et al., 
2021), further experiments with patient-specific cell lines and different 
neurotoxic versus non-neurotoxic therapies are needed to separate un-
specific epiphenomena of neuronal injury or cellular stress response 
from biologically meaningful mechanisms for the pathogenesis of neu-
rodegeneration and pain. 
4.4. iPSC-DSN as a platform to evaluate neuroprotective compounds 
Previously, our research group and others demonstrated that 
lithium, a medication used to treat bipolar disorder, can attenuate 
paclitaxel-induced peripheral (Mo et al., 2012; Sanchez et al., 2020) and 
central (Huehnchen et al., 2017) neuronal damage in cell and animal- 
based models. We thus tested lithium ions as neuroprotectant in iPSC- 
DSN treated with paclitaxel (Sproule, 2002), and found moderate dose 
dependent neuroprotective effects of lithium in concentrations in clini-
cally applied concentrations. These results encourage the use of iPSC- 
DSN as a preclinical animal-free platform for drug discovery. 
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4.5. Outlook - Cell line dependent toxicity as a marker to predict 
differential susceptibility to CIPN? 
An important clinical characteristic of CIPN is that about 20–30% of 
patients receiving different chemotherapeutic regimes do not develop 
CIPN at all and the other 70–80% develop CIPN to varying degrees 
(Boehmerle et al., 2014; Seretny et al., 2014). In this study, we used iPSC 
from two different healthy donors of different sex and ethnicity who 
never underwent chemotherapy. It remains to be shown whether iPSC- 
derived sensory neurons would predict CIPN susceptibility to specific 
compounds for individual patients and potentially even help identify 
preventive treatments. The two cell lines we applied had different sus-
ceptibilities to neurotoxic chemotherapy. Dependent on regimen and 
observation period, the prevalence of CIPN increases up to 80% (Seretny 
et al., 2014), which highlights the necessity to establish tools to monitor, 
predict and prevent CIPN. While genome wide association studies out-
lined certain SNP loci as genetic risk factors (Mahmoudpour et al., 2018) 
and serum neurofilament light chain (sNFL) shows potential as 
biomarker of chemotherapy-induced neuroaxonal damage in rodents 
(Meregalli et al., 2020) and patients (Kim et al., 2020), the individual 
prediction of side effects is not yet possible for CIPN. Previously, donor- 
specific susceptibility to doxorubicin-induced cardiomyopathy could be 
recapitulated in iPSC-derived cardiomyocytes from patients with and 
without heart failure after chemotherapy (Burridge et al., 2016). These 
findings encourage the establishment of iPSC-derived neuronal models 
to study the underlying mechanisms of the individual susceptibility to 
neurotoxic effects. This will be possible when experimental results from 
cell lines of patients with and without CIPN are combined with the 
clinical phenotype. 
Animal models for CIPN have been used for decades (Boehmerle 
et al., 2015; Cavaletti et al., 1992; Boehmerle et al., 2006; Röytta and 
Raine, 1985), despite some differences in their clinical presentation or 
electrophysiological properties (reviewed by Rostock et al. (2018), 
Eldridge et al. (2020)) and ethical issues. Recent studies foster the idea 
to apply reduced DRG-based in-vitro systems as they reproduce the same 
biological and physiologic responses known from whole animal models 
(Li et al., 2021), which also held true in iPSC-DSN. Stem-cell based 
neuronal models may complement these in-vitro approaches of pain and 
neurodegeneration research, along with essentially contributing to the 
3R principle. 
5. Conclusions 
In summary, this study establishes the feasibility of human iPSC-DSN 
to model biological effects of chemotherapy induced neurotoxicity. 
Substance specific effects of neurotoxicity were observed upon treat-
ment with clinically relevant concentrations of neurotoxic chemo-
therapy. Unbiased global transcriptome analyses confirmed the 
expression of relevant genes and gene sets known from animal models, 
and the previously demonstrated neuroprotective effects of lithium 
could be replicated in the human iPSC-DSN model. This underlines its 
potential utility investigating the pathomechanisms of CIPN and enables 
the development of novel neuroprotective strategies. Different sensi-
tivities of iPSC-DSN derived from different healthy donors may hint 
towards individually determined CIPN vulnerability known from pa-
tients. The possibility to relate multi-omic data to functional readouts 
and clinical phenotype encourages patient-specific approaches to study 
the underlying mechanisms of CIPN in vitro. This could facilitate the 
discovery of individual predictive markers and the development of 
therapies to prevent or treat neurodegeneration and neuropathic pain. 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.nbd.2021.105391. 
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versitätsmedizin Berlin and Berlin Institute of Health. PH is the recipient 
of a Rahel-Hirsch fellowship funded by the Charité Universitätsmedizin 
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